Jupiter Neurosciences signs exclusive U.S. rights deal for ALA-002

Jupiter Neurosciences said Tuesday it signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity status. The deal could be worth up to $100 million and turns the company into a dual clinical-stage CNS developer alongside its Parkinson’s program.

Why it matters: - Jupiter Neurosciences is adding a second clinical-stage central nervous system asset, reducing its dependence on a single program. - The ALA-002 deal gives Jupiter perpetual exclusive U.S. rights to a patented psychedelic candidate with FDA Novel Chemical Entity designation. - The agreement creates a U.S. commercialization path in a market Jupiter and PharmAla say could grow as psychedelic medicine policy opens up.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for ALA-002. - The announcement was made Tuesday from Jupiter, Florida. - The transaction covers perpetual exclusive rights in the United States. - Jupiter said the deal could be worth up to $100 million, including milestone payments and excluding ongoing royalties.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in JUNS common stock. - The stock portion carries a 120-day lock-up. - Jupiter would owe $3.3 million at Phase 3 first patient in. - Jupiter would owe $20 million upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales reach $333 million, $1 billion and $2 billion. - A 3% royalty on net sales begins after the third commercialization milestone. - ALA-002 is a non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - The designation provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 is engineered to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving its pro-social and therapeutic properties. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - Jupiter said the arrangement should accelerate development timelines. - Jupiter’s lead program, JOTROL, is a proprietary enhanced-bioavailability resveratrol formulation currently in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement.

Between the lines: - The deal expands Jupiter from a single-program company into a dual clinical-stage CNS developer. - Management said the combination of a natural resveratrol program and a Novel Chemical Entity diversifies the pipeline. - Jupiter’s leadership linked the transaction to U.S. policy momentum after an April 18, 2026 executive order on access to investigational psychedelic therapies. - The order directed federal agencies to expand access paths, including Right to Try and expedited FDA review vouchers for certain psychedelic drugs. - The company also pointed to federal funding through ARPA-H for psychedelic medicine programs. - These policy changes do not remove clinical and regulatory risk, but they may shorten the path for eligible programs.

What's next: - Jupiter said focus now shifts to clinical execution and capital allocation across both CNS assets. - PharmAla will keep advancing ALA-002 outside the United States. - Jupiter must still clear closing conditions, advance trials and seek regulatory approvals before any commercial milestones can be reached. - Future value creation depends on Phase 3 entry, NDA progress and eventual U.S. market uptake.

The bottom line: - Jupiter has bought itself a broader CNS pipeline and a shot at a U.S. psychedelic therapeutics market, but the next value drivers remain clinical and regulatory milestones.